Biological substrates and organelle multi-targeted photosensitizers for ultra-efficient cancer treatment through photodynamic therapy (PDT) are highly desirable. Herein, a multiple pyridinium-anchored photosensitizer containing the triphenylamine unit, TPA-2PI, has been designed and utilized for DNA and mitochondria dual-targeted two-photon-excited bioimaging and PDT. TPA-2PI possesses an ultrahigh ABDA consumption rate of 194.84 nmol min−1 in PBS medium, and an ultralow IC50 value of 0.108 μM upon white-light irradiation (80 mW cm−2, 6 min). After irradiation, the abnormal mitochondria have been remarkable occurred in 4T1 cells and further induced cell apoptosis for the efficient PDT efficacy by TPA-2PI. Upon two-photon excitation (λex = 960 nm), the green fluorescence signal of DCFH-DA showed a dramatic turn-on effect. Furthermore, TPA-2PI could penetrate deeper cells (24 μm) and abdominal blood vessels (384 μm). The investigation of the TPA-2PI-triggered PDT effect in vivo further validated the efficacy of cancer cell ablation and significant inhibition of tumor growth. Moreover, the immunofluorescence staining results and blood biochemical parameters after treatment proved the bio-safety of TPA-2PI. The dual-targeted TPA-2PI can serve as a desirable photosensitizer for efficient cancer treatment, and this work sheds light on the development of biological substrate and organelle multi-targeted photosensitizers for future biological applications.
Organelle-targeted two-photon near-infrared photosensitizers are highly desirable for photodynamic therapy (PDT) of cancer. Herein, in this contribution, we have developed a 2-dicyanomethylenethiazole-based D–π–A structured near-infrared photosensitizer (TTR). TTR exhibits near-infrared emission (704 nm), a large Stokes shift (200 nm), and smaller ΔE S1 – T1 (the energy gap between S1 and T1) (0.717 eV). In vitro results show that TTR can specifically target lysosomes in living cells for near-infrared fluorescence imaging. With efficient ROS generation, excellent biocompatibility, two-photon imaging capability, and depth imaging (21 μm in vitro and 210 μm in vivo), TTR can effectively kill tumor cells and inhibit the growth of subcutaneous tumors. The hematoxylin–eosin (H&E) staining and blood biochemical parameter results further prove the biocompatibility of TTR. Hence, TTR can be a promising photosensitizer for PDT.
Pyroptosis is an inflammatory form of programmed cell death with great potential in cancer immunotherapies. Photodynamic therapy (PDT) represents a promising treatment modality to trigger pyroptosis. However, the hypoxic microenvironment inside the tumors often induces limited therapeutic efficacy. Herein, in this work, the first type of mitochondrial-targeting oxime-ester photogenerator (T-Oximer) was constructed to boost type-I ROS/aryl free radicals which could induce DNA damage by DNA cleaving and facilitate high-efficiency pyroptosis-mediated photoimmunotherapy. Detailed mechanism investigations revealed that T-Oximer could produce aryl free radicals via photolysis reaction and generate type-I ROS (O2•− and •OH) based on the type-I electron transfer process. Meanwhile, T-Oximer could accumulate in the mitochondria, boost mitochondrial radicals, and damage mitochondria in hypoxic tumor cells. Of peculiar interest, T-Oixmer could bind with DNA and cleave DNA to induce DNA damage. Combined mitochondrial damage with DNA cleavage, T-Oximer can initiate pyroptosis, activate the ICD effect, and trigger robust systemic antitumor immunity for efficient tumor regression and metastasis suppression. Our finding provides a new strategy for constructing oxygen-independent photogenerator for high-efficiency pyroptosis-mediated anti-hypoxia photoimmunotherapy.